The incident user design in comparative effectiveness research

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 1, 2013, Pages 1-6

  Johnson, Eric S ^a   Bartman, Barbara A ^b   Briesacher, Becky A ^c   Fleming, Neil S ^d   Gerhard, Tobias ^e   Kornegay, Cynthia J ^f   Nourjah, Parivash ^b   Sauer, Brian ^g   Schumock, Glen T ^h   Sedrakyan, Art ⁱ   Stürmer, Til ^j   West, Suzanne L ^k   Schneeweiss, Sebastian ^l  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d BAYLOR HEALTH CARE SYSTEM   (United States)

^e RUTGERS UNIVERSITY   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

^j IL   (United States)

^k RTI INTERNATIONAL   (United States)

^l BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

Comparative effectiveness; Inception cohort; Incident interventions; Pharmacoepidemiology; Study design

Indexed keywords

ARTICLE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; DRUG MARKETING; FOLLOW UP; HUMAN; PRIORITY JOURNAL; STUDY DESIGN;

BIAS (EPIDEMIOLOGY); COHORT STUDIES; COMPARATIVE EFFECTIVENESS RESEARCH; HUMANS; PHARMACOEPIDEMIOLOGY; RESEARCH DESIGN; TIME FACTORS;

EID: 84872163962     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3334     Document Type: Article

References (30)

1. Vandenbroucke JP. When are observational studies as credible as randomized trials? Lancet 2004; 363: 1728-1731.
2. Schneeweiss S, Patrick AR, Stürmer T, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Medical Care 2007; 45(Suppl 2): S131-S142.
3. Perrio M, Waller PC, Shakir SAW. An analysis of the exclusion criteria used in observational pharmacoepidemiological studies. Pharmacoepidemiol Drug Safety 2007; 16: 329-336.
4. Friedman LM, Furberg CD, DeMets DL. Blindness (chapter 7). In Fundamentals of Clinical Trials (4th edn). Springer: New York, 2010; 119-132.
5. Ray WA. Evaluating medication effects outside of clinical trials: new user designs. Am J Epidemiol 2003; 158: 915-920.
6. Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005; 162: 404-414.
7. Petitti DB, Freedman DA. Invited commentary: How far can epidemiologists get with statistical adjustment? Am J Epidemiol 2005; 162: 415-418.
8. Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiol 2008; 19: 766-779.
9. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-625.
10. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
11. Ray WA, Stein CM, Daughtery JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-1073.
12. McMahon AD, MacDonald TM. Design issues for drug epidemiology. Br J Clin Pharmacol 2000; 50: 419-425.
13. Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994; 47: 731-737.
14. Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML. Good research practices for comparative effectiveness research: Approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force-Part II. Value Health 2009; 12: 1053-1061.
15. Guess HA. Exposure-time-varying hazard function ratios in case-control studies of drug effects. Pharmacoepidemiol Drug Saf 2006; 15: 81-92.
16. UKPDS Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
17. Feinstein AR. Clinical epidemiology III: The clinical design of statistics in therapy. Ann Intern Med 1968; 69: 1287-1312.
18. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med 2007; 4: e297. DOI: 10.1371/journal.pmed.0040297.
19. Jacobus S, Schneeweiss S, Chan KA. Exposure misclassification as a result of free sample drug utilization in automated claims databases and its effect on pharmacoepidemiologic studies of selective COX-2 inhibitors. Pharmacoepidemiol Drug Saf 2004; 13: 695-702.
20. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population-based cohort study using the QResearch database. BMJ 2010; 340: c2197. DOI: 10.1136/bmj.c2197.
21. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336: 1114-1117.
22. Hallas J, Gaist D, Bjerrum L. The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization. Epidemiology 1997; 8: 666-670.
23. Hernán MA, Cole SR, Margolick J, Cohen M, Robins JM. Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiol Drug Saf 2005; 14: 477-491.
24. Stürmer T, Glynn RJ, Kliebsch U, Brenner H. Analytic strategies for recurrent events in epidemiologic studies: background and application to hospitalization risk in the elderly. J Clin Epidemiol 2000; 53: 57-64.
25. Knipschild P, Leffers P, Feinstein AR. The qualification period. J Clin Epidemiol 1991; 44: 461-464.
26. Schneeweiss S, Patrick AR, Solomon DH, et al. Variation in the risk of suicide attempts and completed suicides by antidepressant agents in adults: a propensity score-adjusted analysis of 9 years' data. Arch Gen Psych 2010; 67: 497-506.
27. Solomon DH, Lunt M, Schneeweiss S. The risk of infection associated with TNF antagonists: making sense of epidemiologic evidence. Arthritis Rheum 2008; 58: 919-928.
28. Short PF, Graefe DR, Schoen C. Churn, churn, churn: how instability of health insurance shapes America's uninsured problem. Issue brief, The Commonwealth Fund. New York, NY, 2003.
29. Fleming TR. Current issues in non-inferiority trials. Statist Med 2008; 27: 317-332.
30. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c332. DOI: 10.1136/bmj.c332.